计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
BAY 1125976是一种选择性的变构AKT1/2抑制剂,对小鼠模型中AKT信号依赖性的肿瘤生长具有较强功效。在10 µM ATP时BAY 1125976对 AKT1、AKT2和AKT3的ic50分别为 5.2 nM、18 nM和427 nM,在2 mM ATP时BAY 1125976对AKT1和AKT2的ic50分别为 44 nM和36 nM。
Information
BAY 1125976 is a selective allostericAKT1/2inhibitor,exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. BAY1125976 inhibits the activity ofAKT1(IC50 = 5.2 nM at 10 µM ATP and 44 nM at 2 mM ATP) andAKT2(IC50 = 18 nM at 10 µM ATP and 36 nM at 2 mM ATP) very potently.Whereas BAY1125976 is almost inactive onAKT3(IC50 = 427 nM at 10 µM ATP).
Targets
Akt1 (at 10 µM ATP); Akt2 (at 10 µM ATP); Akt2 (at 2 mM ATP); Akt1 (at 2 mM ATP); Akt3 (at 10 µM ATP) 5.2 nM; 18 nM; 36 nM; 44 nM; 427 nM
In vitro
BAY 1125976 inhibits activation of AKT in cell lines carrying the AKT-activating mutation E17K. In KU-19-19 bladder cancer cells activation by phosphorylation is inhibited at AKT1-S473 and 4EBPI-T70 with IC50 values of 35 and 100 nM, respectively. In the prostate cancer cell line LAPC-4, the phosphorylation of AKT1-S473, T308 and 4EBP1-T70 is inhibited with IC50 values of 0.8, 5.6 and 35 nM, respectively. Treatment of LAPC-4 cells with BAY 1125976 results in an inhibition of PRAS40 phosphorylation at T246 as a direct target of AKT1 activity with an IC50 of ∼141 nM. BAY 1125976 inhibits the proliferation of the breast cancer cell lines BT-474, T47D, MCF7, ZR-75–1, EVSA-T, MDA-MB-453, KPL-4 and BT20 as well as the prostate cancer cell lines LNCaP and LAPC-4 with submicromolar IC50 values. Breast cancer cell lines of luminal type show strong inhibition of cell proliferation following BAY 1125976 treatment..
In vivo
Treatment with different doses of BAY 1125976 results in potent antitumor efficacy in KPL-4 tumor bearing mice. A clear, statistically significant dose-response is observed after daily oral treatment with 25 or 50 mg/kg BAY 1125976 with T/Cvolume ratios of 0.14 and 0.08, respectively. Daily administration of 25 or 50 mg/kg BAY 1125976 results in significant antitumor efficacy in MCF7-implanted nude mice compared with the control with T/Cvolume values of 0.25 and 0.25 and T/Cweight values of 0.33 and 0.37, respectively. BAY 1125976 displays good antitumor efficacy in vivo in AKT1E17K mutated models..
Cell Research(from reference)
Cell lines:13 human breast cancer cell lines and 10 other cancer cell lines
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 唑类 |
| 亚类(Subclass) | 咪唑类 |
| 中间层级节点(Intermediate Tree Nodes) | 取代咪唑 |
| 直接上位类(Direct Parent) | 苯基咪唑类 |
| 其他上位类(Alternative Parents) | 2-杂芳基酰胺 芳烷基胺 哒嗪及其衍生物 N-取代咪唑 苯及其取代衍生物 杂芳族化合物 伯羧酸酰胺 氨基酸及其衍生物 氮杂环化合物 有机氧化合物 有机氧化物 单烷基胺 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 2-异芳基甲酰胺 - 4-苯基吡啶 - 5-苯基咪唑 - 氨基酸 - 氨基酸或其衍生物 - 芳烷基胺 - 芳香族杂多环化合物 - 氮杂环 - 苯基化合物 - 羧酰胺基 - 羧酸衍生物 - 杂芳香族化合物 - 烃衍生物 - 单环苯基基团 - N-取代咪唑 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 初级脂肪胺 - 初级胺 - 醛基胺 - 吡嗪 |
| 描述(Description) | 该化合物属于苯并咪唑类有机化合物。这类多环芳香族化合物通过碳碳键或氰基键将苯环与咪唑环相连。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | Akt2, IC50: 18 nM; Akt2, IC50: 36 nM |
|---|---|
| ALogP | 3.335 |
| hba_count | 3 |
| HBD Count | 2 |
| Rotatable Bond | 4 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|